Calidi Biotherapeutics Presents New Data on CLD-401 at SITC Annual Meeting.
ByAinvest
Monday, Nov 10, 2025 8:06 am ET1min read
CLDI--
Calidi Biotherapeutics presented new data on its first therapeutic candidate, CLD-401, at the Society of Immunotherapy for Cancer Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to target metastatic sites, replicate only in tumor cells, induce immune priming, and express high levels of IL-15 superagonist, a potent cytokine. The data showed that the RedTail platform is protected from immune clearance and can specifically replicate in tumor cells at metastatic sites.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet